An observational study in Peripheral Vascular Embolization, sponsored by Shape Memory Medical, Inc.. Active, not recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.
Sponsored by Shape Memory Medical, Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
EMBO-PMS is a prospective, multicentre, registry study of the IMPEDE and IMPEDE-FX Embolization Plug Systems
Shape Memory Medical, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult study participants considered candidates for a peripheral vascular embolization procedure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Peripheral vascular embolization
Safety - Rate of freedom from serious adverse events
Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor
Time frame: 30 days
Efficacy - Rate of technical success (embolization of target vessel)
Technical success, defined as embolization of the target area after deployment of the study device
Time frame: Immediately after the intervention
Efficacy - Rate of recurrence of clinical symptoms, based on original complaint
Number of participants free of recurrent clinical symptoms, based on clinical symptoms of original complaint
Time frame: 90 days
Efficacy - Rate of treated vessel occlusion
Treated vessel occlusion, measured per study site standard of care for the original condition treated
Time frame: 90 days
Safety - Rate of freedom from serious adverse events
Rate of freedom from serious adverse events related to the study devices and/or procedure, per review and adjudication by medical monitor
Time frame: 90 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2019 to primary completion in Aug 2025, 73 months.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shape Memory Medical, Inc.